TY - JOUR
T1 - Reoperation in recurrent high-grade gliomas
T2 - Literature review of prognostic factors and outcome
AU - Brandes, Alba A.
AU - Vastola, Francesca
AU - Monfardini, Silvio
PY - 1999/8
Y1 - 1999/8
N2 - Two percent of cancer deaths are caused by malignant primary brain tumors, and most of these are high-grade gliomas. Despite the treatment given, malignant gliomas recur early. Mean survival is less than 12 months, and only 20% of patients survive for more than 2 years. This rapid course induces some physicians to resort to all the therapeutic options available and, at recurrence, to reevaluate the patient for a second intervention. Others consider reoperation to be an overtreatment. The debate is ongoing, and an answer likely will be found only through better identification of the prognostic factors that will identify patients who will benefit from reoperation.
AB - Two percent of cancer deaths are caused by malignant primary brain tumors, and most of these are high-grade gliomas. Despite the treatment given, malignant gliomas recur early. Mean survival is less than 12 months, and only 20% of patients survive for more than 2 years. This rapid course induces some physicians to resort to all the therapeutic options available and, at recurrence, to reevaluate the patient for a second intervention. Others consider reoperation to be an overtreatment. The debate is ongoing, and an answer likely will be found only through better identification of the prognostic factors that will identify patients who will benefit from reoperation.
KW - Prognostic factors
KW - Recurrent high-grade gliomas
KW - Reoperation
UR - http://www.scopus.com/inward/record.url?scp=0033502353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033502353&partnerID=8YFLogxK
U2 - 10.1097/00000421-199908000-00013
DO - 10.1097/00000421-199908000-00013
M3 - Article
C2 - 10440196
AN - SCOPUS:0033502353
VL - 22
SP - 387
EP - 390
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 4
ER -